NASDAQ:ENDP - Endo International Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.09 +0.26 (+2.40 %)
(As of 07/18/2018 02:30 PM ET)
Previous Close$10.88
Today's Range$10.87 - $11.30
52-Week Range$5.27 - $12.52
Volume200,064 shs
Average Volume6.30 million shs
Market Capitalization$2.36 billion
P/E Ratio2.91
Dividend YieldN/A
Endo International logoEndo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio-1,161.84
Current Ratio1.06
Quick Ratio0.88


Trailing P/E Ratio2.91
Forward P/E Ratio4.68
P/E Growth4.46

Sales & Book Value

Annual Sales$3.47 billion
Price / Sales0.72
Cash Flow$8.8016 per share
Price / Cash1.26
Book Value$2.17 per share
Price / Book5.11


EPS (Most Recent Fiscal Year)$3.84
Net Income$-2,035,430,000.00
Net Margins-75.58%
Return on Equity143.46%
Return on Assets6.30%


Outstanding Shares223,790,000
Market Cap$2,363.23

The Truth About Cryptocurrencies

Endo International (NASDAQ:ENDP) Frequently Asked Questions

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

How were Endo International's earnings last quarter?

Endo International PLC (NASDAQ:ENDP) posted its earnings results on Tuesday, May, 8th. The company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.55 by $0.12. The firm had revenue of $700.53 million for the quarter, compared to analyst estimates of $691.94 million. Endo International had a positive return on equity of 143.46% and a negative net margin of 75.58%. The company's revenue for the quarter was down 32.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.23 earnings per share. View Endo International's Earnings History.

When is Endo International's next earnings date?

Endo International is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Endo International.

What guidance has Endo International issued on next quarter's earnings?

Endo International issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $2.15-2.55 for the period, compared to the Thomson Reuters consensus estimate of $2.34. The company issued revenue guidance of $2.6-2.8 billion, compared to the consensus revenue estimate of $2.74 billion.

What price target have analysts set for ENDP?

18 brokerages have issued 12 month price targets for Endo International's stock. Their predictions range from $7.00 to $16.00. On average, they expect Endo International's stock price to reach $9.3667 in the next year. This suggests that the stock has a possible downside of 16.1%. View Analyst Ratings for Endo International.

What is the consensus analysts' recommendation for Endo International?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 1 sell rating, 13 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Endo International stock?

Here are some recent quotes from research analysts about Endo International stock:
  • 1. According to Zacks Investment Research, "Endo is in the process of redefining its business given the persistent decline in the generic business due to the loss of marketing exclusivity for the first-to-file products ezetimibe tablets and quetiapine ER tablets. The branded pharmaceuticals business was impacted by continued generic competition for established products, product divestitures and ceasing shipments of Opana ER and this is expected to continue further. Endo withdrew opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June 2017. The focus now is on sterile injectables and Xiaflex. While the turnaround might take time, the company seems to be on the right track. However, we expect challenging business conditions for the company in 2018. Shares have underperformed the industry in the last twelve months." (7/16/2018)
  • 2. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) Executing well against its stated objectives in U.S. generics, during 4Q17, the U.S. generics segment launched six products and submitted two regulatory filings. In 2017, the U.S. generics segment launched 17 products and ENDP made 12 regulatory submissions. As of 12/31/17, ENDP had ~100 ANDAs (~1/3 FTF/FTM) pending with the FDA. 2) Sterile Injectables is a growing franchise. Sterile Injectables revenue increased 16% YOY. This increase was driven by Adrenalin. 3) Important sterile injectable drugs include Vasostrict and Adrenalin. ENDP reported 2017 Vasostrict sales of $400MM and Adrenalin sales of $77MM. 4) As of 12/31/17, ENDP had $987MM in unrestricted cash, net debt of ~$7.3B and a net leverage ratio of 4.6x. 5) 4Q17 cash provided by operating activities was $132MM, compared to $84MM of net cash provided by operating activities in 2016. 6) Cellulite could be a big opportunity for ENDP. RELEASE-1 And RELEASE-2 Phase 3 trials looking at Xiaflex for the treatment cellulite were initiated. Topline data are expected 1Q19. ENDP plans to submit all the data in 2019. ENDP expects to commercialize the product on its own, but would consider strategic alternatives. 7) ENDP thinks that the generic market seems more stable, but it is still early in 2018." (2/27/2018)
  • 3. Mizuho analysts commented, "We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued." (1/3/2018)

Are investors shorting Endo International?

Endo International saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 44,378,306 shares, an increase of 16.9% from the June 15th total of 37,956,086 shares. Based on an average daily trading volume, of 8,093,073 shares, the days-to-cover ratio is currently 5.5 days. Currently, 22.2% of the shares of the company are sold short. View Endo International's Current Options Chain.

Who are some of Endo International's key competitors?

Who are Endo International's key executives?

Endo International's management team includes the folowing people:
  • Mr. Paul V. Campanelli, Pres, CEO & Director (Age 56)
  • Mr. Blaise Coleman, Exec. VP & CFO (Age 44)
  • Mr. Terrance J. Coughlin, Exec. VP & COO (Age 52)
  • Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 46)
  • Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 61)

Has Endo International been receiving favorable news coverage?

News articles about ENDP stock have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endo International earned a daily sentiment score of 0.11 on Accern's scale. They also gave media stories about the company an impact score of 44.72 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Endo International's major shareholders?

Endo International's stock is owned by many different of institutional and retail investors. Top institutional investors include Xact Kapitalforvaltning AB (0.02%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel and Terrance J Coughlin. View Institutional Ownership Trends for Endo International.

Which major investors are buying Endo International stock?

ENDP stock was purchased by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International.

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $11.17.

How big of a company is Endo International?

Endo International has a market capitalization of $2.36 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]

MarketBeat Community Rating for Endo International (NASDAQ ENDP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  717 (Vote Outperform)
Underperform Votes:  637 (Vote Underperform)
Total Votes:  1,354
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Featured Article: What does RSI mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.